Abstract
Routine screening mammography has increased the incidence of stage I breast cancers. Many more women are being diagnosed with lymph node-negative tumors that are less than or equal to 1 cm in greatest diameter. The National Surgical Adjuvant Breast and Bowel Project recently performed a retrospective analysis of 10,302 women participating in one of five clinical trials, including women with lymph node-negative breast cancer. Of these women, 1259 had tumors less than or equal to 1 cm. The analysis of the women with tumors less than or equal to 1 cm revealed an improved relapse-free survival (RFS) if tamoxifen was given after surgery, compared with surgery alone, for women with estrogen receptor (ER)-positive tumors; and for women with ER-negative tumors, RFS was improved by delivering chemotherapy after surgery. The authors suggested that adjuvant systemic therapy should be considered for anyone with an invasive breast cancer, regardless of the size of the tumor. This paper reviews the data presented in that important, historic article, and discusses their conclusions. Also reviewed are the most recent recommendations for treatment of primary breast cancer from the International Consensus Panel that convened at the Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer in St. Gallen, Switzerland. That panel also addressed the issue of adjuvant systemic therapy in women considered to have a minimal or low risk of developing recurrent disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Rosen PP, Groshen S, Kinne DW, Norton L: Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993, 11:2090–2100.
Leitner SP, Swern AS, Weinberger D, et al.: Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer 1995, 76:2266–2274.
Lee AK, Loda M, Mackarem G, et al.: Lymph node negative invasive breast cancer 1 centimeter or less in size (T1a,bN0M0): clinicopathologic features and outcome. Cancer 1997, 79:761–771.
Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S: Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995, 13:1144–1151.
Fisher B, Dignam J, Tan-Chiu E, et al.: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001, 93:112–120. This paper provides long-term prognostic information and outcome data on 1259 women with lymph node-negative invasive breast cancer less than 1 cm. Long-term recurrence-free survival and overall survival are evaluated in this group of women stratified by hormone receptor status and adjuvant systemic therapy received. This is the largest published analysis of women with this very small breast cancer.
Fisher B, Anderson S, Redmond C, et al.: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995, 333:1456–1461.
Fisher B, Dignam J, Mamounas EP, et al.: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996, 14:1982–1992.
Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479–484.
Fisher B, Dignam J, Bryant J, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88:1529–1542.
Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89:1673–1682.
Lippman ME, Hayes DF: Adjuvant therapy for all patients with breast cancer? J Natl Cancer Inst 2001, 93:80–82. This is an editorial of the Fisher article listed as reference [5]. It provides thoughtful commentary and insight into the value of the data being presented in that trial, while criticizing some of the authors’ conclusions. This editorial should be read in concert with reference [5].
Goldhirsch A, Glick JH, Gelber RD, et al.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 2001, 18:3817–3827. This paper is an updated summary of recommendations for the surgical and adjuvant systemic therapy of early breast cancer. An international panel of breast cancer experts meets every 2 to 4 years to review all of the critical new trial results and scientific studies concerning early breast cancer. At the conclusion of their review, recommendations and guidelines are published. The 2001 guidelines are presented.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Russell, C.A. Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm. Curr Oncol Rep 5, 72–77 (2003). https://doi.org/10.1007/s11912-003-0090-y
Issue Date:
DOI: https://doi.org/10.1007/s11912-003-0090-y